Generate Life Sciences Supports Rutgers Cancer Institute’s Cord Blood Research With Critical Bioprocessing Device Donation
– The Sepax 2 S-100 device will add cellular therapy preparation capabilities to the work being conducted by the Department of Pediatric Hematology/Oncology at Rutgers Cancer Institute of New Jersey in collaboration with Robert Wood Johnson University Hospital
Published: October 13, 2021 at 10:45 AM MDT|Updated: 5 minutes ago
LOS ANGELES, Oct. 13, 2021 /PRNewswire/ — Generate Life Sciences announced today that it is donating a Sepax 2 S-100 cell bioprocessing system manufactured by Cytiva to Rutgers Cancer Institute in New Jersey to support research into the potential efficacy of umbilical cord blood infusions in various brain lesions in children.
Between life and science is an opportunity (PRNewsfoto/Generate Life Sciences)
Cytiva’s Sepax 2 S-100 is a closed system bioprocessor that prepares cells for infusion from umbilical cord blood, also known as newborn stem cells*, and other blood derivatives, while preserving the quality of the cells and protecting them from contamination. With this device, Rutgers researchers in collaboration with researchers at Robert Wood Johnson University Hospital are now able to conduct clinical trials using umbilical cord blood cells for a wide variety of indications, and participate in a global effort to expand access to these therapies. to expand.
“Umbilical cord blood is a promising therapeutic modality, particularly for pediatric neurological conditions that have no cure today,” says Archana Sharma, DO, a pediatric hematologist/oncologist at Rutgers Cancer Institute, who conducts cord blood testing. “Much research remains to be done to fully understand the optimal application of these cells for therapy, and our Rutgers team looks forward to doing its part in this effort. We are grateful to Generate Life Sciences for their contribution to Cytiva equipment, adding a new critical capacity for our research team and enabling us to participate in future stem cell-based studies.”
“We believe that newborn stem cells will play a key role in the next generation of regenerative medicine,” said Jaime Shamonki, MD, Generate’s Chief Medical Officer. “There are numerous active clinical trials around the world promoting stem cell therapies, particularly in areas of high need, such as neurological disabilities in children. We welcome the opportunity to work with groups, such as Rutgers, to improve access to this much need. clinical trial opportunities with newborn stem cells for as many children as possible.”
Generate Life Sciences believes that everyone has the right to take advantage of the latest scientific advances to grow and protect their families. This donation helps ensure more families have access to newborn stem cell therapies and builds on existing initiatives at Generate:
Cord Blood Advantage Program, which provides free newborn stem cell preservation to families of donor-begotten children using Generate’s reproductive tissue services Family Health Registry, which actively collects information about conditions within the immediate family that may be treated with newborn stem cells so that teach clients about relevant clinical trial options and potentially contribute to new research Newborn Possibilities Program, which enables families with a qualifying medical need to receive free newborn stem cell processing, plus five years of free storage
Generate’s family of companies includes four of the world’s largest newborn stem cell banks – Cord Blood Registry, Insception Lifebank, Cells for Life and Cell Care – and they are well positioned to power studies in the field of regenerative medicine, either through a repository of stem cells available for research, contract manufacturing projects, or clinical development partnerships.
For more information about the Sepax 2 S-100, visit the Cytiva product website.
*Newborn stem cell is a broad term for cells derived from the umbilical cord, including cord tissue-derived mesenchymal stem cells (MSCs) and cord blood-derived hematopoietic stem cells (HSCs).
About Generate Life Sciences
Generate Life Sciences® is a global life sciences company serving families from preconception to adulthood by providing guidance and services grounded in accurate science. Our longstanding brands — including CBR® (Cord Blood Registry®), Insception Lifebank, Cells for Life, Cell Care, California Cryobank™, Donor Egg Bank USA™, NW Cryobank™, ReadyGen™, Kitazato USA™ and Donor Application™ — are pioneering leaders who have helped nearly a million families through reproductive, newborn stem cell, genetic screening, medical devices and healthcare technology. Generate, headquartered in Los Angeles, operates facilities in the United States, Canada and Australia, in addition to distributing frozen donor gametes to more than 40 countries. Generate is a portfolio company of GI Partners, a private investment firm based in San Francisco.
View original content to download multimedia:
SOURCE Generate Life Sciences
The above press release was provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group, nor do they necessarily represent those of Gray Media Group, Inc.